Hotta et al., 2011 - Google Patents
Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic reviewHotta et al., 2011
View HTML- Document ID
- 15020205163490593097
- Author
- Hotta K
- Kiura K
- Fujiwara Y
- Takigawa N
- Hisamoto A
- Ichihara E
- Tabata M
- Tanimoto M
- Publication year
- Publication venue
- PloS one
External Links
Snippet
Background In advanced non-small-cell lung cancer (NSCLC), with the increasing number of active compounds available in salvage settings, survival after progression to first-line chemotherapy seems to have improved. A literature survey was conducted to examine …
- 230000004083 survival 0 title abstract description 44
Classifications
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/53—Immunoassay; Biospecific binding assay
- G01N33/574—Immunoassay; Biospecific binding assay for cancer
- G01N33/57407—Specifically defined cancers
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by the preceding groups
- G01N33/48—Investigating or analysing materials by specific methods not covered by the preceding groups biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
- G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
- G01N33/5011—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics for testing antineoplastic activity
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06Q—DATA PROCESSING SYSTEMS OR METHODS, SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES; SYSTEMS OR METHODS SPECIALLY ADAPTED FOR ADMINISTRATIVE, COMMERCIAL, FINANCIAL, MANAGERIAL, SUPERVISORY OR FORECASTING PURPOSES, NOT OTHERWISE PROVIDED FOR
- G06Q50/00—Systems or methods specially adapted for a specific business sector, e.g. utilities or tourism
- G06Q50/01—Social networking
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F21/00—Security arrangements for protecting computers, components thereof, programs or data against unauthorised activity
- G06F21/60—Protecting data
- G06F21/62—Protecting access to data via a platform, e.g. using keys or access control rules
- G06F21/6218—Protecting access to data via a platform, e.g. using keys or access control rules to a system of files or objects, e.g. local or distributed file system or database
-
- G—PHYSICS
- G06—COMPUTING; CALCULATING; COUNTING
- G06F—ELECTRICAL DIGITAL DATA PROCESSING
- G06F19/00—Digital computing or data processing equipment or methods, specially adapted for specific applications
- G06F19/10—Bioinformatics, i.e. methods or systems for genetic or protein-related data processing in computational molecular biology
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Hotta et al. | Role of survival post-progression in phase III trials of systemic chemotherapy in advanced non-small-cell lung cancer: a systematic review | |
Meyer et al. | The receptor AXL diversifies EGFR signaling and limits the response to EGFR-targeted inhibitors in triple-negative breast cancer cells | |
Davies et al. | Real-world treatment patterns for patients receiving second-line and third-line treatment for advanced non-small cell lung cancer: a systematic review of recently published studies | |
Oze et al. | Twenty-seven years of phase III trials for patients with extensive disease small-cell lung cancer: disappointing results | |
McGrail et al. | Improved prediction of PARP inhibitor response and identification of synergizing agents through use of a novel gene expression signature generation algorithm | |
Jayson et al. | Antiangiogenic therapy—evolving view based on clinical trial results | |
Lara Jr et al. | Disease control rate at 8 weeks predicts clinical benefit in advanced non–small-cell lung cancer: results from Southwest Oncology Group randomized trials | |
Grassi et al. | Clinical impact of pancreatic metastases from renal cell carcinoma: a multicenter retrospective analysis | |
Zhang et al. | Prognostic value of epidermal growth factor receptor mutations in resected non-small cell lung cancer: a systematic review with meta-analysis | |
Chen et al. | Gefitinib or erlotinib as maintenance therapy in patients with advanced stage non-small cell lung cancer: a systematic review | |
Hu et al. | A quantitative chemotherapy genetic interaction map reveals factors associated with PARP inhibitor resistance | |
Huang et al. | An updated meta-analysis of fatal adverse events caused by bevacizumab therapy in cancer patients | |
Díaz-Rubio et al. | Role of Kras status in patients with metastatic colorectal cancer receiving first-line chemotherapy plus bevacizumab: a TTD group cooperative study | |
Chen et al. | Both carboplatin and bevacizumab improve pathological complete remission rate in neoadjuvant treatment of triple negative breast cancer: a meta-analysis | |
Hotta et al. | Progression-free survival and overall survival in phase III trials of molecular-targeted agents in advanced non-small-cell lung cancer | |
Hempel et al. | Real world data analysis of next generation sequencing and protein expression in metastatic breast cancer patients | |
Palma et al. | Durable response to crizotinib in a MET-amplified, KRAS-mutated carcinoma of unknown primary | |
van der Noord et al. | An increased cell cycle gene network determines MEK and Akt inhibitor double resistance in triple-negative breast cancer | |
Pflugfelder et al. | Effectiveness of carboplatin and paclitaxel as first-and second-line treatment in 61 patients with metastatic melanoma | |
Jung et al. | Increased VEGF-A in solid type of lung adenocarcinoma reduces the patients’ survival | |
Louie et al. | Precision medicine‐based therapies in advanced colorectal cancer: The University of California San Diego Molecular Tumor Board experience | |
Yavuz et al. | Pan-cancer clinical impact of latent drivers from double mutations | |
Catalano et al. | The impact of age, performance status and comorbidities on nab-paclitaxel plus gemcitabine effectiveness in patients with metastatic pancreatic cancer | |
Moretto et al. | Benefit from upfront FOLFOXIRI and bevacizumab in BRAFV600E-mutated metastatic colorectal cancer patients: does primary tumour location matter? | |
Chen et al. | Telomere-related prognostic biomarkers for survival assessments in pancreatic cancer |